Advertisement
Advertisement
EBS
Emergent Biosolutions, Inc.
10.91
USDSponsored
+0.38
+3.56%
Feb 06, 16:00 UTC -5
Closed
After-Market
10.84
-0.08
-0.73%
EBS Earnings Reports
Positive Surprise Ratio
EBS beat 21 of 40 last estimates.
53%
Next Report
Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
$219.68M
/$0.11
Implied change from Q3 25 (Revenue/ EPS)
-4.94%
/-89.62%
Implied change from Q4 24 (Revenue/ EPS)
+12.83%
/+120.00%
Emergent Biosolutions, Inc. earnings per share and revenue
On Oct 29, 2025, EBS reported earnings of 1.06 USD per share (EPS) for Q3 25, beating the estimate of -0.12 USD, resulting in a 974.59% surprise. Revenue reached 231.10 million, compared to an expected 195.94 million, with a 17.94% difference. The market reacted with a +36.60% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of 0.11 USD, with revenue projected to reach 219.68 million USD, implying an decrease of -89.62% EPS, and decrease of -4.94% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Emergent Biosolutions, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Emergent Biosolutions, Inc. reported EPS of $1.06, beating estimates by 974.59%, and revenue of $231.10M, 17.94% above expectations.
How did the market react to Emergent Biosolutions, Inc.'s Q3 2025 earnings?
The stock price moved up 36.6%, changed from $9.40 before the earnings release to $12.84 the day after.
When is Emergent Biosolutions, Inc. expected to report next?
The next earning report is scheduled for Mar 02, 2026.
What are the forecasts for Emergent Biosolutions, Inc.'s next earnings report?
Based on 4
analysts, Emergent Biosolutions, Inc. is expected to report EPS of $0.11 and revenue of $219.68M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement